Want to see AU:ENP full AI Analyst Report?
Total Valuation
Tryptamine Therapeutics has a market cap or net worth of AU$66.98M. The enterprise value is AU$47.56M.
Market CapAU$66.98M
Enterprise ValueAU$47.56M
Share Statistics
Tryptamine Therapeutics has 1,633,593,800 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding1,633,593,800
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Tryptamine Therapeutics’s return on equity (ROE) is -0.66 and return on invested capital (ROIC) is -66.04%.
Return on Equity (ROE)-0.66
Return on Assets (ROA)-0.58
Return on Invested Capital (ROIC)-66.04%
Return on Capital Employed (ROCE)-0.92
Revenue Per Employee0.00
Profits Per Employee-1.22M
Employee Count4
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Tryptamine Therapeutics is ―. Tryptamine Therapeutics’s PEG ratio is 0.50.
PE Ratio―
PS Ratio0.00
PB Ratio6.82
Price to Fair Value6.82
Price to FCF-14.72
Price to Operating Cash Flow-20.25
PEG Ratio0.50
Income Statement
In the last 12 months, Tryptamine Therapeutics had revenue of 0.00 and earned -4.87M in profits. Earnings per share was >-0.01.
Revenue0.00
Gross Profit-27.34K
Operating Income-6.77M
Pretax Income-6.78M
Net Income-4.87M
EBITDA-6.74M
Earnings Per Share (EPS)>-0.01
Cash Flow
In the last 12 months, operating cash flow was -3.41M and capital expenditures -5.57K, giving a free cash flow of -3.41M billion.
Operating Cash Flow-3.41M
Free Cash Flow-3.41M
Free Cash Flow per Share>-0.01
Dividends & Yields
Tryptamine Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.45
52-Week Price Change-2.38%
50-Day Moving Average0.04
200-Day Moving Average0.03
Relative Strength Index (RSI)58.86
Average Volume (3m)1.55M
Important Dates
Tryptamine Therapeutics upcoming earnings date is Feb 26, 2025, TBA (Confirmed).
Last Earnings DateSep 6, 2024
Next Earnings DateFeb 26, 2025
Ex-Dividend Date―
Financial Position
Tryptamine Therapeutics as a current ratio of 7.94, with Debt / Equity ratio of 0.00%
Current Ratio7.94
Quick Ratio7.94
Debt to Market Cap0.00
Net Debt to EBITDA0.83
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Tryptamine Therapeutics has paid -1.91M in taxes.
Income Tax-1.91M
Effective Tax Rate0.28
Enterprise Valuation
Tryptamine Therapeutics EV to EBITDA ratio is -6.62, with an EV/FCF ratio of -13.08.
EV to Sales0.00
EV to EBITDA-6.62
EV to Free Cash Flow-13.08
EV to Operating Cash Flow-13.10
Balance Sheet
Tryptamine Therapeutics has AU$5.58M in cash and marketable securities with AU$0.00 in debt, giving a net cash position of AU$5.58M billion.
Cash & Marketable SecuritiesAU$5.58M
Total DebtAU$0.00
Net CashAU$5.58M
Net Cash Per Share<AU$0.01
Tangible Book Value Per Share<AU$0.01
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Tryptamine Therapeutics is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast29.55%